Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

(currently amended) A process for preparing a compound of formula (I)

where R⁴ and R⁵ are independently selected from hydrogen,-halo,-nitro,-cyano,-hydroxy,
fluoromethyl, difluoromethyl, trifluoromethyl, trifluoromethyl, amino, carboxy,
earbameyl, mercapto, sulphameyl, ureido, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy,
C₁₋₆alkanoyl, C₁₋₆alkanoyloxy, N-(C₁₋₆alkyl)amino, N-N-(C₁₋₆alkyl)amino,
C₁₋₆alkanoylamino, N-(C₁₋₆alkyl)amino, N-N-(C₁₋₆alkyl)amino,
C₁₋₆alkanoylamino, N-(C₁₋₆alkyl)amino, N-N-(C₁₋₆alkyl)amino,
N-(C₁₋₆alkyl)amino, N-(C₁₋₆alkyl)amino,
N-(C₁₋₆alkyl)amino, N-(C₁₋₆alkyl)amino, N-(C₁₋₆alkyl)amino, N-(C₁₋₆alkyl)amino, N-(C₁₋₆alkyl)amino,

W-(G_{+e}alkyl)sulphamoyl, N,N-(G_{+e}alkyl)_ssulphamoyl, C_{+e}alkylsulphonylamino and G_{+e}alkylsulphonyl-W-(G_{+e}alkyl)amino; and R⁶ is hydrogen or a protecting group,

which process comprises cyclisation of a compound of formula (II)

where R^4 , R^5 and R^6 are as defined in relation to formula (I), and R^7 is a nitrogen protecting group; and

removing the group R7;

and thereafter optionally removing any protecting group R6.

2. (previously presented) A process according to claim 1 wherein R^7 is a group of sub-formula (i)

where R⁸ is a straight chain alkyl group of from 1 to 6 carbon atoms.

3-11 (cancelled)

 (previously presented) A process according to claim 1, for preparing a compound of formula (I) where R⁶ is hydrogen, wherein the process further comprises the step of reacting the compound of formula (I) obtained with an amine of formula (XIII)

where R^{14} is selected from hydrogen or C_{1-8} alkyl, m is an integer of from 0 to 4,

each R¹⁶ is the same or different and is selected from hydrogen, halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, ureido, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy, C₁₋₆alkanoyl, C₁₋₆alkanoyloxy, *N*-(C₁₋₆alkyl)amino, *N*,*N*-(C₁₋₆alkyl)amino, C₁₋₆alkanoylamino, *N*-(C₁₋₆alkyl)carbamoyl, *N*,*N*-(C₁₋₆alkyl)zcarbamoyl, C₁₋₆alkyl)sulphamoyl, *N*,*N*-(C₁₋₆alkyl)sulphamoyl, C₁₋₆alkylsulphamoyl, *N*,*N*-(C₁₋₆alkyl)sulphamoyl, C₁₋₆alkylsulphonyl-N-(C₁₋₆alkyl)amino, C₃₋₆cycloalkyl, C₃₋₆cycloalkyl, aryl, arylC₁₋₆alkyl, heterocyclic group and (heterocyclic group)C₁₋₆alkyl; wherein R¹⁵ may be optionally substituted on carbon by one or more groups selected from P and wherein if said heterocyclic group contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R;

each R^{16} is the same or different and is selected from hydrogen or $C_{\text{1-6}} \text{alkyl};$

R¹⁷ is selected from hydrogen, halo, nitro, cyano, hydroxy, fluoromethyl, difluoromethyl,

Application No. 10/528,612 Amendment Dated 06/25/2007 Reply to Office Action of 02/26/2007

 $C_{1:6} alkyl sulphonyl amino carbonyl, \ C_{1:6} alkyl sulphonyl- \textit{N-}(C_{1:6} alkyl) amino \ and \ a \ group -E-F-G-H:$

- wherein E and G are independently selected from a direct bond, -O-, -S-, -SO-, -SO-2-, -OC(O)-, -C(O)O-, -C(O)-, -NRa-, -NRaC(O)-, -C(O)NRa-, -NRa-SO-2-, -NRa-C(O)NRb-, -OC(O)NRa-, -NRa-C(O)O-, -NRa-SO-2NRb-, -SO-2NRa-C(O)- and -C(O)NRa-SO-2-; wherein Ra and Rb are independently selected from hydrogen or C_{1-0} alkyl which is optionally substituted by a group V:
- F is C₁₋₆alkylene optionally substituted by one or more Q or a direct bond;
- H is selected from aryl, C₃₋₆cycloalkyl and heterocyclic groups; wherein H may be optionally substituted on carbon by one or more groups selected from S and wherein if said heterocyclic group contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from T:
- P, S and Q are independently selected from halo, nitro, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, ureido, $C_{1:6}$ alkyl, $C_{2:6}$ alkenyl, $C_{2:6}$ alkoxyl, $C_{1:6}$ alkoxy, $C_{1:6}$ alkoxyl, $C_{1:6}$ alkoxyl, $C_{1:6}$ alkyl)amino, N_i C($C_{1:6}$ alkyl)amino, $C_{1:6}$ alkyl
 - $N,N-(C_{1-6}alkyl)_2$ carbamoyl, $N-(C_{1-6}alkyl)-N-(C_{1-6}alkoxy)$ carbamoyl, $C_{1-6}alkylS(O)_a$ wherein a is 0 to 2, $C_{1-6}alkoxy$ carbonyl, $C_{1-6}alkoxy$ carbonylamino, $N-(C_{1-6}alkyl)$ sulphamoyl, $N,N-(C_{1-6}alkyl)$ sulphamoyl, $C_{1-6}alkyl$ sulphonylamino,
 - C_{1-6} alkylsulphonyl-N- $(C_{1-6}$ alkyl)amino, C_{3-6} cycloalkyl, aryl and heterocyclic group; wherein P, S and Q may be optionally and independently substituted on carbon by one or more groups selected from V and wherein if said heterocyclic group contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from U;
- V is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, actoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, M-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, N-dimethylcarbamoyl, N-M-dimethylcarbamoyl, N-methylcarbamoyl, N-methylcarbamoyl, M-methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulphamoyl, N-methylsulphamoyl,
- R, T and U are independently selected from C₁₋₄alkyl, C₁₋₄alkanoyl, C₁₋₄alkylsulphonyl, C₁₋₄alkylcarbamovl, N-(C₁₋₄alkyl)carbamovl, N-N-(C₁₋₄alkyl)carbamovl, phenyl,

N- benzylcarbamoyl, and 4-hydroxypiperidinocarbonyl;

10/528,612 06/25/2007 02/26/2007

benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl wherein R, T and U may be optionally and independently substituted on carbon by one or more groups selected from V:

producing a compound of formula (XIV)

$$\mathbb{R}^{4} \xrightarrow{\mathbb{N}} \mathbb{N} \mathbb{N}^{14} \xrightarrow{\mathbb{N}^{15}} \mathbb{R}^{15}$$

$$\mathbb{R}^{5} \xrightarrow{\mathbb{N}^{16}} \mathbb{R}^{17}$$

$$\mathbb{R}^{15} \xrightarrow{\mathbb{N}^{16}} \mathbb{R}^{17}$$

$$\mathbb{R}^{15} \xrightarrow{\mathbb{N}^{16}} \mathbb{R}^{17}$$

$$\mathbb{R}^{15} \xrightarrow{\mathbb{N}^{16}} \mathbb{R}^{17}$$

where R⁴, R⁵, R¹⁵, R¹⁶, R¹⁷ and m are as defined above, or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

13-15. (cancelled)